Načítá se...
Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
There have been unique adverse events reported with targeted blockade of programmed death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA4), including immune mediated toxicities. Recently, there have been reports of hepatitis B reactivation (HBVr) o...
Uloženo v:
| Vydáno v: | J Immunother |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7946380/ https://ncbi.nlm.nih.gov/pubmed/33480637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000358 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|